Our Science
A Breakthrough Within Reach
Behind every Alzheimer’s disease blood test powered by ALZpath is one thing: our proprietary pTau217 antibody, an engineered tool that precisely detects even tiny amounts of the pTau217 protein in blood. Developed for accuracy, built for access, and backed by world-class science, this tool is helping redefine how – and when – Alzheimer’s disease pathology is detected.
The Science Behind Earlier Answers
We believe everyone deserves to understand their risk for Alzheimer’s disease – early enough to act. That belief drives us. It is why we developed a proprietary monoclonal antibody that detects pTau217, a highly reliable early biomarker of Alzheimer’s, strongly linked to amyloid buildup in the brain.
This breakthrough enables detection of Alzheimer’s pathology up to 15 years before symptoms appear – using a simple blood test.
ALZpath’s proprietary pTau217 antibody is emerging as the new gold standard for blood-based Alzheimer’s disease detection.
Making Answers Accessible
Our proprietary pTau217 monoclonal antibody powers the next generation of Alzheimer’s disease tests – developed and distributed by the world’s leading diagnostics companies – including Beckman Coulter Diagnostics, Roche, Bio-Techne, Alamar Biosciences, and Quanterix.
In comparison studies, pTau217 tests powered by ALZpath have matched the diagnostic performance of more established diagnostic tools like:
- PET imaging, which detects amyloid plaques and/or tau tangles in the brain, the hallmarks of Alzheimer’s disease pathology
- Cerebrospinal fluid (CSF) testing, which requires a lumbar puncture to measure protein levels Unlike these traditional approaches, a pTau217 blood test is non-invasive, scalable, highly accessible, and significantly more affordable – making earlier detection possible in everyday care settings.
Published data in JAMA Neurology and other leading journals continue to validate its performance and clinical utility.
What is pTau217 – and Why Does it Matter?
Alzheimer’s disease begins silently, years before clinical symptoms emerge. One of the earliest detectable signs is the accumulation of abnormal amyloid-beta protein plaques in the brain. Notably, the presence of phosphorylated tau at threonine 217 (pTau217) has emerged as a highly promising diagnostic tool as it closely mirrors the accumulation of amyloid-beta and helps detect Alzheimer’s pathology at an early stage.
This makes pTau217 a critical component in the development of non-invasive, cost-effective, and scalable blood tests with potential use in the early detection and monitoring of Alzheimer’s disease progression.
How pTau217 Testing is Used
For individuals over 55 with evidence of cognitive decline
A pTau217 blood test can help clarify whether Alzheimer’s disease pathology may be contributing to symptoms– reducing diagnostic uncertainty and guiding next steps.
Where research is heading
The following applications are investigational and not currently approved for clinical use
For individuals at risk but not yet symptomatic
Ongoing studies are exploring the role of pTau217 in identifying Alzheimer’s disease pathology in people with genetic or familial risk – potentially years before symptoms appear. This research may open the door to earlier interventions, lifestyle planning, and clinical trial participation.
For monitoring treatment response
Preliminary research suggests that pTau217 levels may change in response to certain Alzheimer’s disease therapies. While not yet validated or approved for treatment monitoring, scientists are investigating whether pTau217 could serve as a simpler, more accessible alternative to PET imaging or spinal fluid tests in the future.
How to Order the Test
For Physicians
ALZpath-powered pTau217 tests will be available through leading global diagnostics companies. Contact us to find out more.
The ALZpathDx test, powered by our proprietary pTau217 antibody, is available today through NeurocodeUSA, a CLIA-certified lab. Testing is available across the United States (application pending in New York) and through BC Neuroimmunology in Canada.
Simply complete a requisition form from Neurocode. Collection kits can be delivered to your office or the patient’s home, and blood draws can be done in-clinic or at a local site. Turnaround time is typically 3-10 business days.
For Researchers
RUO tests using our pTau217 antibody are available from our partners. We also collaborate to develop new tests using our antibody. To request more information, please complete the form below.
"*" indicates required fields
Frequently Asked Questions
Q: How is ALZpathDx used in Alzheimer’s disease diagnosis?
A: ALZpathDx helps detect Alzheimer’s disease pathology in people at risk for the disease (55 years or older) experiencing cognitive changes. Elevated pTau217 levels may indicate Alzheimer’s pathology and help differentiate it from other dementias. While a full diagnosis combines multiple assessments, ALZpathDx is a valuable complementary tool.
Q: Can I or a family member order the test directly?
A: Today, a physician must order ALZpathDx through Neurocode.
Q: Is ALZpathDx available outside the United States and Canada?
A: Yes, contact us to learn more.
Want to Know More?
Connect With Us
If you’re interested in learning more about ALZpath or want to know more about our work, we’d love to talk with you.